Esperion Receives the US FDA's Approval for Nexlizet (Non-Statin LDL-Cholesterol Lowering Therapy)
Shots:
- The approval is based on P-III FDC LDL-C lowering program assessing Nexlizet (bempedoic acid and ezetimibe) vs PBO and the safety data of Nexletol (bempedoic acid) in pivotal P-III LDL-C lowering program with the existing ezetimibe safety profile
- The P-III study resulted in lowering the LDL-C by 38% when added on to maximally tolerated statins and is well tolerated. The approval follows the approval of Nexletol (bempedoic acid) received on Feb 21- 2020 with its anticipated availability in the US in Mar’2020
- Nexlizet (PO- qd) is the first non-statin LDL-cholesterol lowering combination therapy- indicated as an adjunct to diet and maximally tolerated statin therapy for HeFH/ established ASCVD in patients requiring additional lowering of LDL-C with its expected availability in the US in July’2020
Click here to read full press release/ article | Ref: Esperion | Image: Seek Vector Logo
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com